Advance Search

Magnitude and Determinants of Biochemical Mineral Bone Disease Abnormalities among Predialysis Chronic Kidney Disease Patients in Tikur Anbessa Specialized Hospital

Sirak Melkeneh
a:1:{s:5:"en_US";s:22:"Addis Ababa University";}
Addisu Melkie
Copyright and Licensing:

Copyright (c) 2025 Ethiopian Medical Journal

Creative Commons License

This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.

Share:
  • Articles
  • Submited: April 26, 2023
  • Published: January 1, 2025

Abstract

Introduction: Mineral bone disease (MBD) abnormalities are common complications in patients with chronic kidney disease (CKD). The MBD abnormalities are known to be associated with increased morbidity and mortality. In spite of their importance, there is limited data on CKD-MBD abnormalities in Ethiopia. This study looked in to the magnitude and factors associated with biochemical CKD-MBD abnormalities among predialysis CKD patients.    

Methods: A cross-sectional study was conducted from July 1 to September 30, 2020 in Tikur Anbessa specialized hospital. One hundred patients who have had follow-up for at least 6 months with estimated glomerular filtration rate (eGFR) <60ml/min/1.73m2 using CKD-EPI equation without race factor were included. Serum calcium, albumin, phosphorus and PTH levels were determined. Demographic and clinical data were collected using a structured questionnaire. IBM SPSS software version 26 was used for analysis.

Results: Among the 100 patients included in this study; the median age was 58 years with IQR of 73. The male to female ratio was 2.7:1. Patients in stages 3a, 3b, 4 and 5 CKD accounted for 23%, 29%, 26% and 22% respectively. The main causes of CKD were diabetes and hypertension. Among the patients 31% had hyperphosphatemia, 36% had hypocalcemia, and 89% had hyperparathyroidism. Estimated GFR correlated negatively with serum parathyroid hormone (PTH) level but correlated positively with serum calcium level. The mean values of calcium in CKD stage 3a,3b,4 and 5 were 8.91, 8.81, 8.7 and 7.14mg/dl respectively where as those of serum phosphorus were 3.58, 3.83, 3.83 and 5.53mg/dl respectively. The median values of PTH were 140.6, 137.2, 274.05 and 440.85Pg/ml respectively.

Conclusion: Hypocalcemia, hyperparathyroidism, and hyperphosphatemia are common biochemical CKD-MBD abnormalities among predialysis CKD patients in renal clinic of Tikur Anbessa specialized hospital. Monitoring for CKD‑MBD should begin earlier on and treatment should be initiated accordingly to improve patient outcome. 

PDF
PDF

Downloads

Download data is not yet available.

References

  1. Coresh J, Astor BC, Greene T, Eknoyan G, Levey AS. Prevalence of chronic kidney disease and decreased kidney function in the adult US population: Third National Health and Nutrition Examination Survey. American Journal of Kidney Diseases. 2003;41(1):1–12.
  2. Abd Elhafeez S, Bolignano D, D’Arrigo G, Dounousi E, Tripepi G, Zoccali C. Prevalence and burden of chronic kidney disease among the general population and high-risk groups in Africa: A systematic review. BMJ Open. 2018;8(1).
  3. Kumela Goro K, Desalegn Wolide A, Kerga Dibaba F, Gashe Fufa F, Wakjira Garedow A, Edilu Tufa B, et al. Patient Awareness, Prevalence, and Risk Factors of Chronic Kidney Disease among Diabetes Mellitus and Hypertensive Patients at Jimma University Medical Center, Ethiopia. BioMed Research International. 2019;2019.
  4. 2012 K. KDIGO 2012 CKD Guideline. Vol. 19, IFAC Proceedings Volumes (IFAC-PapersOnline). 2014.
  5. Isakova T, Nickolas TL, Denburg M, Yarlagadda S, Weiner DE, Gutiérrez OM, et al. KDOQI US Commentary on the 2017 KDIGO Clinical Practice Guideline Update for the Diagnosis, Evaluation, Prevention, and Treatment of Chronic Kidney Disease–Mineral and Bone Disorder (CKD-MBD). American Journal of Kidney Diseases. 2017;70(6):737–51.
  6. Tentori F, Blayney MJ, Albert JM, Gillespie BW, Kerr PG, Bommer J, et al. Mortality Risk for Dialysis Patients With Different Levels of Serum Calcium, Phosphorus, and PTH: The Dialysis Outcomes and Practice Patterns Study (DOPPS). American Journal of Kidney Diseases. 2008;52(3):519–30.
  7. Block GA, Klassen PS, Lazarus JM, Ofsthun N, Lowrie EG, Chertow GM. Mineral metabolism, mortality, and morbidity in maintenance hemodialysis. Journal of the American Society of Nephrology. 2004;15(8):2208–18.
  8. Kestenbaum B, Sampson JN, Rudser KD, Patterson DJ, Seliger SL, Young B, et al. Serum phosphate levels and mortality risk among people with chronic kidney disease. Journal of the American Society of Nephrology. 2005;16(2):520–8.
  9. Levin A, Bakris GL, Molitch M, Smulders M, Tian J, Williams LA, et al. Prevalence of abnormal serum vitamin D, PTH, calcium, and phosphorus in patients with chronic kidney disease: Results of the study to evaluate early kidney disease. Kidney International. 2007;71(1):31–8.
  10. Okoye JU, Arodiwe EB, Ulasi II, Ijoma CK, Onodugo OD. Prevalence of CKD-MBD in pre-dialysis patients using biochemical markers in enugu, south-east Nigeria. African Health Sciences. 2015;15(3):941–8.
  11. Vikrant S, Parashar A. Prevalence and severity of disordered mineral metabolism in patients with chronic kidney disease: A study from a tertiary care hospital in India. Indian Journal of Endocrinology and Metabolism. 2016;20(4):460–7.
  12. Căpușă C, Chirculescu B, Vladu I, Viaşu L, Lipan M, Moţa E, et al. The prevalence of biochemical abnormalities of chronic kidney disease. Mineral and bone disorders in untreated non-dialysis patients – A multicenter study. Acta Endocrinologica. 2016;12(3):282–90.
  13. Valson AT, Sundaram M, David VG, Deborah MN, Varughese S, Basu G, et al. Profile of incident chronic kidney disease related-mineral bone disorders in chronic kidney disease Stage 4 and 5: A hospital based cross-sectional survey. Indian Journal of Nephrology. 2014;24(2):97–107.
  14. Sanusi AA. Prevalence and Pattern of Renal Bone Disease in End Stage Renal Disease. West African Journal of medicine. 2010;29(2):75–80.
  15. Han S woo, Kim S jin, Lee D joo, Kim K min, Joo N seok. The Relationship between Serum 25-Hydroxyvitamin D , Parathyroid Hormone and the Glomerular Filtration Rate in Korean Adults : The Korea National Health and Nutrition Examination Survey between 2009 and 2011. 2014;35(2):98–106.
  16. Goldsmith DJA, Covic AA, Venning MC, Ackrill P. Blood Pressure Reduction After Parathyroidectomy for Secondary Hyperparathyroidism: Further Evidence Implicating Calcium Homeostasis in Blood Pressure Regulation. 1996;27(6):819–25.
  17. Simeoni M, Perna AF, Fuiano G. Secondary Hyperparathyroidism and Hypertension : An Intriguing Couple. 2020;(Figure 1):1–9.
  18. Massry S.G., Iseki K. CVM. Serum Calcium, Parathyroid Hormone, and Blood Pressure. Am J Nephrol. 1986;6(Suppl. 1):19–28.
  19. Gupta A, Kallenbach LR, Zasuwa G, Divine GW. Race is a major determinant of secondary hyperparathyroidism in uremic patients. Journal of the American Society of Nephrology. 2000;11(2):330–4.
  20. Prince RL. COUNTERPOINT : Estrogen Effects on Calcitropic Hormones and Calcium Homeostasis. 2015;15(3):301–9.
  21. Behradmanesh S, Hamid Nasri. Association of serum calcium with level of blood pressure in type 2 diabetic patients. Journal of Nephropathology. 2013;2(4):254–7.
  22. Reichel H, Liebethal R, Schmidt-gayk HHH, Ritz E. Clinical Investigator Disturbed calcium metabolism in subjects with elevated diastolic blood pressure. 1992;25:748–51.
How to Cite
Melkeneh, S., & Melkie, A. (2025). Magnitude and Determinants of Biochemical Mineral Bone Disease Abnormalities among Predialysis Chronic Kidney Disease Patients in Tikur Anbessa Specialized Hospital. Ethiopian Medical Journal, 63(1). Retrieved from https://emjema.org/index.php/EMJ/article/view/2367

Send mail to Author

Send Cancel